Skip to content
  • Insights Newsletter

    Always Be a Step Ahead

    Learn the important healthcare trends that could affect you in advance. Get expert analysis and discover the innovative ideas that are helping businesses overcome today's challenges.

    Subscribe to AMI's Insights Newsletter Today.

     

  • Login
  • Contact
  • Subscribe
  • Insights Newsletter

    Always Be a Step Ahead

    Learn the important healthcare trends that could affect you in advance. Get expert analysis and discover the innovative ideas that are helping businesses overcome today's challenges.

    Subscribe to AMI's Insights Newsletter Today.

     

  • Login
Access Market IntelligenceAccess Market Intelligence
  • Menu
  • About
    • Dr. Randy Vogenberg
    • John Santilli
    • News Announcements
    • Contact
  • Shop Reports
    • Filter By
      • Discounted
      • Latest Releases
    • Report Topic or Type
      • Ebooks
      • Provider Trends
      • Payor Trends
      • Purchaser Trends
      • Market Access & Distribution
  • Solutions
    • Data and Intelligence Platforms
      • Employer Sales Initiatives
    • Advisory and Consulting Services
      • Virtual Advisory Board for Healthcare
      • Strategy Development
      • Health Benefit Training
      • Custom Market Research
    • Specialty Pharmacy Database
  • Resources
    • Insights Blog
    • Sample Reports
    • Free Publications
  • Specialty Pharmacy Database
    • Blog – Specialty Pharmacy
    • SPD Case Study
    • SPD Request for Information
  • $0.00 0
    • No products in the cart.

  • Shop
  • 0

    Cart

    No products in the cart.

Tag Archives: metastatic PDGFRA Exon 18 mutant gastrointestinal

Specialty Drug, Specialty Pharmacy, Uncategorized

Genentech (Roche) and Blueprint Medicines Collaborate to Increase Market Access

Posted on November 5, 2020 by John Santilli
05
Nov

Both Gavreto and AYVAKIT are available through Blueprint’s specialty distribution network and two specialty pharmacies: Biologics by McKesson and PantherRx

Continue reading →
Posted in Specialty Drug, Specialty Pharmacy, Uncategorized  |  Tagged Accelerated Approval, avapritinib, AYVAKIT, Biolgics by McKesson, biologics, Blueprint, Blueprint Medicines, cancer, comercialize, commercialization, FDA FDA approval, Gavreto, Genentech, GIST, I/II ARROW study, lung cancer, market access, metastatic PDGFRA Exon 18 mutant gastrointestinal, metastatic rearranged during transfection, non-small cell lung cancer, NSCLC, Oncology, PantherRare, PantherRx, patient assistance program, pralsetinib, RET, Roche, YourBlueprint

Copyright 2023 © Access Market Intelligence. All Rights Reserved  |  Terms of Service 

  • Login
  • Home
  • Reports
    • View Samples
    • What’s New
    • On Sale
    • eBooks
    • By Market
      • Payor
      • Purchaser
      • Provider
      • Market Access & Distribution
  • Services
    • Virtual Advisory Board
    • Strategy Development
    • Health Benefit Training
    • Market Research
  • Data Solutions
    • Specialty Pharmacy Database (SPD)
    • Employer Sales Initiatives
  • Resources
    • Blog
    • Free Downloads
  • About
    • Contact

Login

Lost your password?

Register